36) Ghia AJ et al : Phase 1 Study of Spinal Cord Constraint Relaxation With Single Session Spine Stereotactic Radiosurgery in the Primary Management of Patients With Inoperable, Previously Unirradiated Metastatic Epidural Spinal Cord Compression. Int. J. Radiat. Oncol. Biol. Phys. 102 : 1481-1488, 2018
37) Ma TM et al : Volume effects in radiosurgical spinal cord dose tolerance : how small is too small? Journal of Radiation Oncology 8 : 53-61, 2019
38) Sahgal A et al. : Spinal Cord Dose Tolerance to Stereotactic Body Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys., 2019
39) Sahgal A et al : Reirradiation human spinal cord tolerance for stereotactic body radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 82 : 107-116, 2012
40) Cox BW et al : Esophageal toxicity from high-dose, single-fraction paraspinal stereotactic radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 83 : e661-667, 2012
41) Ito K et al : A prospective multicentre feasibility study of stereotactic body radiotherapy in Japanese patients with spinal metastases. Jpn. J. Clin. Oncol. 49 : 999-1003, 2019
42) Ito K et al : Stereotactic Body Radiotherapy for Spinal Metastases : Clinical Experience in134 Cases From a Single Japanese Institution. Technol. Cancer Res. Treat. 17 : 1533033818806472, 2018
43) Ito K et al : Efficacy and toxicity of re-irradiation spine stereotactic body radiotherapy with respect to irradiation dose history. Jpn. J. Clin. Oncol. 51 : 264-270, 2021
44) Sangha A et al : Stereotactic Body Radiotherapy for the Treatment of Spinal Metastases. An Overview of the University of Toronto, Sunnybrook Health Sciences Odette Cancer Centre, Technique. J Med Imaging Radiat Sci 44 : 126-133, 2013
45) Marchand EL et al : Treatment planning and delivery evaluation of volumetric modulated arc therapy for stereotactic body radiotherapy of spinal tumours : impact of arc discretization in planning system. Technol. Cancer Res. Treat. 11 : 599-606, 2012
46) ユーロメディテック株式会社 医学物理室 治療計画トライアル. Available from : https://medphys.euro-meditec.co.jp/planQA/ (accessed on 1 April 2021)
47) Weksberg DC et al : Generalizable class solutions for treatment planning of spinal stereotactic body radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 84 : 847-853, 2012
48) Videtic GM et al : A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer : NRG Oncology RTOG 0915 (NCCTG N0927). Int. J. Radiat. Oncol. Biol. Phys. 93 : 757-764, 2015
49) ACOSOG Z4099/RTOG 1021 protocol : A Randomized Phase III Study of Sublobar Resection (+/-Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).
50) Cheng ZJ et al : On the accuracy of dose prediction near metal fixation devices for spine SBRT. J. Appl. Clin. Med. Phys. 17 : 475-485, 2016
a) RTOG 0631 protocol : Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis.
b) SC.24 protocl A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients With Spinal Metastases.
c) Palma DA, Olson R, Harrow S, et al. : Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET) : a randomised, phase 2, open-label trial. Lancet 393 : 2051-2058, 2019
d) Benedict SH, Yenice KM, Followill D, et al. : Stereotactic body radiation therapy : the report of AAPM Task Group 101. Med. Phys. 37 : 4078-4101, 2010
e) Videtic GM, Hu C, Singh AK, et al. : A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer : NRG Oncology RTOG 0915 (NCCTG N0927). Int. J. Radiat. Oncol. Biol. Phys. 93 : 757-764, 2015
f) ACOSOG Z4099/RTOG 1021 protocol : A Randomized Phase III Study of Sublobar Resection (+/-Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC). g) Pollom EL, Chin AL, Diehn M, et al. : Normal Tissue Constraints for Abdominal and Thoracic Stereotactic Body Radiotherapy. Semin. Radiat. Oncol. 27 : 197-208, 2017
h) Bezjak A, Paulus R, Gaspar LE, et al. : Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer : NRG Oncology/RTOG 0813 Trial. J. Clin. Oncol. 37 : 1316-1325, 2019
i) Manyam BV, Verdecchia K, Videtic GMM, et al. : Validation of RTOG 0813 Proximal Bronchial Tree Constraints for Pulmonary Toxicity With Stereotactic Body Radiation Therapy for Central Non-small Cell Lung Cancer. Int. J. Radiat. Oncol. Biol. Phys. 107 : 72-78, 2020
j) Cox BW, Jackson A, Hunt M, et al. : Esophageal toxicity from highdose, single-fraction paraspinal stereotactic radiosurgery. Int. J. Radiat. Oncol. Biol. Phys. 83 : e661-667, 2012
k) Forquer JA, Fakiris AJ, Timmerman RD, et al. : Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC : doselimiting toxicity in apical tumor sites. Radiother. Oncol. 93 : 408-413, 2009
l) Xue J, Kubicek G, Patel A, et al. : Validity of Current Stereotactic Body Radiation Therapy Dose Constraints for Aorta and Major Vessels. Semin. Radiat. Oncol. 26 : 135-139, 2016
m) Bae SH, Kim MS, Cho CK, et al. : Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for abdominopelvic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 84 : e469-474, 2012
n) Goldsmith C, Price P, Cross T, et al. : Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of Pancreatic Cancer : A Focus on Duodenal Dose Constraints. Semin. Radiat. Oncol. 26 : 149-156, 2016
o) LaCouture TA, Xue J, Subedi G, et al. : Small Bowel Dose Tolerance for Stereotactic Body Radiation Therapy. Semin. Radiat. Oncol. 26 : 157-164, 2016